tbuckley/cabot-search huggingface dataset:
Behavioral Changes Following Participation in a Home Health Promotional Program in King County, Washington
Authors: Rainbow Leung, Jane Q. Koenig, Nancy Simcox, Gerald van Belle, Richard Fenske, Steven G. Gilbert
Journal: Environmental Health Perspectives (1997)

This study examined behavioral changes in households after participation in a home environmental assessment. Home assessment visits by a trained coach, which involved a walk-through in the home with the home residents, were conducted in 36 homes. The walk-through included a list of recommended behavioral changes that the residents could make to reduce their exposures to home pollutants in areas such as dust control, moisture problems, indoor air, hazardous household products, and hobbies. Recruited households were surveyed 3 months after the home assessment to evaluate their implementation of the recommendations. Following the home visits, 31 of 36 households reported making at least one behavioral change, and 41% of the recommendations made by the volunteer coaches were implemented. In conclusion, this study found that the majority of the households who participated in the home assessment reported implementing at least one recommendation. This home health promotional method was effective in influencing behavioral changes.
Manual of Medicine.
Journal: JAMA (1913)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Genetic disorders of human red blood cells
Authors: E. Beutler
Journal: JAMA (1975)

Human red blood cells (RBCs) are subject to an enormous degree of genetic diversity. The variability that occurs may result in anemia, cyanosis, polycythemia, or may cause no hematologic alterations. Genetic abnormalities affecting hemoglobin include the sickling disorders, the unstable hemoglobinopathies, hemoglobinopathies associated with polycythemia or with methemoglobinemia, and the α- and β-thalassemias. The most common enzymatic abnormality of RBCs is glucose-6-phosphate dehydrogenase deficiency, but defects of many other enzymes leading to hemolytic anemia have been identified. Deficiencies of RBC enzymes may also be important in the diagnosis of nonhematologic disease and in the evaluation of dietary status. (<i>JAMA</i>233:1184-1188, 1975)
Oral contraceptive agents and the management of acute intermittent porphyria
Authors: M. G. Perlroth
Journal: JAMA (1965)

Among women with acute intermittent porphyria (AIP) a small group exists whose clinical symptoms are precipitated by menses or pregnancy. In three such cases studied, the cyclical use of the oral progestational agents was apparently successful in preventing the appearance of symptoms. The individual administration of androgen, estrogen, and a progestin preparation to one patient showed the same protective effect. This suggests that inhibition of gonadotropin secretion, with stabilization of endogenous ovarian steroid production at a low level, may be the effective mechanism. Use of the progestins is occasionally associated with signs and symptoms of hepatotoxicity. Such side effects constitute the main limitation in the use of these drugs. Untoward effects can be minimized by the use of alternative preparations and lower dosage.
Randomized phase II trial of sorafenib, capecitabine, and oxaliplatin (SECOX) versus single agent sorafenib in patients with advanced hepatocellular carcinoma.
Authors: Gin Wai Kwok, Vikki Tang, Roland Ching-Yu Leung, Ann-Shing Lee, Ada Law, Joanne Wing Yan Chiu, Bryan Li, Tan To Cheung, Thomas Yau
Journal: Journal of Clinical Oncology (2019)

e15630 Background: We aimed to compare the efficacy and tolerability of SECOX regimen with sorafenib alone as first-line treatment of advanced hepatocellular cancer (HCC) in a multicenter, open-label and randomized setting. Methods: Patients not suitable for surgery or various loco-regional therapies and no prior systemic therapy for advanced HCC were recruited in 3 centres. Eligible patients were randomly assigned to receive either SECOX (sorafenib 400 mg BD continuously, oxaliplatin 85 mg/m 2 on D1, and capecitabine 1700 mg/m 2 on D1-7 q2w) or sorafenib alone continuously in 1:1 ratio. Primary endpoint was time-to-progression (TTP). Secondary endpoints were tolerability, overall tumor response rate, overall survival (OS) and progression-free survival (PFS). Results: Forty-six patients were randomized and treated, of whom 22 were in the SECOX arm. Median age was 64 years and majority of the patients were male (72%). 40 patients (87%) were hepatitis B carrier, and 42 patients (91%) had Child-Pugh A liver function. Thirty patients (65%) had received prior non-systemic treatment for HCC. Median duration of follow-up was 7.8 months (mos) (range 0.3-25.8). At the time of analysis,one patient in the SECOX arm is still receiving treatment. Median TTP was 3.2 mos (95% CI 1.7-5.8) for SECOX vs 2.8 mos (95% CI 1.8-4.0) for sorafenib. The hazard ratio (HR) for TTP was 0.91 (95% CI 0.5-1.7; p = 0.77; predetermined futility boundary HR ≥ 0.86). Median OS was 7.1 mos (95% CI 3.0-15.3) for SECOX vs 12.5 mos (95% CI 7.2-15.4) for sorafenib (p = 0.29). Median PFS was 3.1 mos (95% CI 1.6-5.8) for SECOX vs 2.7 mos (95% CI 1.8-4.0) for sorafenib. 2 patients (9%) and no patients achieved partial response in the SECOX and sorafenib arms, respectively. The clinical benefit rate (CR+PR+SD) was 36% for the SECOX arm and 21% for the sorafenib arm (p = 0.50). Incidence of treatment-related adverse events (trAEs) was common in both SECOX and sorafenib arms (64% and 71% respectively, p = 0.75). The most common grade 3-4 trAE was ALP increase (14%) for SECOX and hand-foot skin reaction (25%) for sorafenib. Conclusions: The addition of capecitabine and oxaliplatin to sorafenib did not result in significant improvement in TTP. Clinical trial information: NCT02716766.
Revision
Authors: Jack Coulehan
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Acute viral hepatitis in adults. Comparison of the radioimmunoassay and counterimmunoelectrophoresis methods of detecting HbsAg
Authors: R. P. Wenzel
Journal: JAMA (1975)

We compared the radioimmunoassay (RIA) and counterimmunoelectrophoretic (CIE) methods in detecting hepatitis B antigen (HB Ag) in 407 acute and 336 convalescent sera of adults with viral hepatitis. The CIE method demonstrated that 41% of acute and 28% of 14- to 17-day serum specimens were HBsAg-positive. The RIA method demonstrated seropositivity in 60% of acute and 56% of convalescent specimens (<i>P</i>&lt;.001). Eightyfour percent of coded specimens initially positive for HB Ag by RIA were found to have subtype antigenic determinants d or y; 92% of the HB Ag-negative controls were negative for subtype antigens, confirming the specificity of the RIA test. RIA subtyping data corroborated earlier work with immunodiffusion techniques. (<i>JAMA</i>232:366-368, 1975)
Tension and hypertension
Authors: T. G. Pickering
Journal: JAMA (1993)

Many patients with high blood pressure consider that the term<i>hypertension</i>refers to an elevation of nervous as well as physical tension, an idea first proposed in 1905 by Gaisböck, who observed that in men with high systolic pressure "one finds an unusual frequency of those who as directors of big enterprises had a great deal of responsibility and who, after long periods of psychic overwork, became nervous."<sup>1</sup>Many physicians, on the other hand, doubt that mental factors play any significant role in the development of hypertension. The study by Markovitz et al<sup>2</sup>in this issue ofTHE JOURNALoffers support for the patients' viewpoint. The concept of a "hypertensive personality" has been debated for about 50 years, but there is still no consensus as to whether it really exists or, if it does, how it should be defined or measured. Three views have been advocated: first, that
Development of Immunoassays for Biomonitoring of Hexamethylene Diisocyanate Exposure
Authors: Ranulfo Lemus, Lina Lukinskeine, Mark E. Bier, Adam V. Wisnewski, Carrie A. Redlich, Meryl H. Karol
Journal: Environmental Health Perspectives (2001)

Hexamethylene diisocyanate (HDI) is used widely to manufacture polyurethanes for paints and coatings. It is an irritant and a chemical asthmagen. The U.S. Occupational Safety and Health Administration time-weighted average permissible exposure limit is 5 ppb and the ceiling limit is 20 ppb. We sought to develop a sensitive and specific immuno-bioassay to supplement workplace air monitoring and detect recent HDI exposure. For this, we produced rabbit antiserum to HDI-adducted keyhole limpet hemocyanin (HDI-KLH). The specificity of the antiserum was demonstrated by its reaction with a variety of HDI-conjugated proteins and the absence of reactions with conjugates of other diisocyanates, namely toluene diisocyanate and diphenyl methylene diisocyanate. Four immunoassays were developed and compared for their ability to detect decreasing quantities of HDI-adducted human serum albumin (HSA) containing 2 mol HDI adduct per mol HSA (HDI(2)-HSA) as determined by matrix-assisted laser desorption time-of-flight (MALDI-TOF) mass spectrometry. The sensitivities of some of the assays are within the range (0.82-45 nM) of current analytic methods. A Western analysis procedure has a sensitivity of 600 nM HDI adduct on HSA. ELISA inhibition assay, in which microtiter plates are coated with the HDI(2)-HSA antigen, has a sensitivity of 300 nM HDI adduct. An immunoblot assay has a sensitivity of 9 nM HDI adduct. The most sensitive bioassay (1.8 nM HDI adduct) is a three-antibody sandwich ELISA in which wells of microtiter plates are coated with the IgG fraction of the anti-HDI-KLH antisera. Compared with analytic methods for HDI biomonitoring, the immunoassays are faster and less costly and accommodate numerous samples simultaneously. The assays have the potential to affect industrial biomonitoring programs significantly.
Editorial: Myocardial depressant factor (MDF) in cardiogenic shock
Authors: S. Vaisrub
Journal: JAMA (1974)

Investigative and therapeutic approaches to cardiogenic shock in acute myocardial infarction have been dominated by hemodynamic considerations. Cardiac output, arterial blood pressure, vasomotor tone, and organ perfusion have been the prime concern of researcher and clinician. Humoral factors, generally related to the sympathetic-adrenergic system, assumed importance only insofar as they influenced the hemodynamics of the circulation. Currently, the focus is shifting to humoral factors as they affect biochemical processes at the cellular level. Several have been shown recently to play an important part in various forms of shock. Most prominent in<i>cardiogenic</i>shock is the<i>myocardial depressant factor</i>(MDF), a small peptide of molecular weight range between 800 and 1,000 discovered in 1966 by Brand and Lefer.<sup>1</sup> Formation of MDF is initiated by vasoconstriction in the splanchnic vascular bed in response to a fall in systemic arterial blood pressure. This commendable homeostatic attempt to shunt blood to vital organs
THE JOURNAL SPECIAL TRAIN.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Targeting PKC in Multiple Myeloma: In Vitro and In Vivo Effects of the Novel, Orally Available Small-Molecule Inhibitor Enzastaurin (LY317615.HCl).
Authors: Marc S. Raab, Klaus Podar, Jing Zhang, Douglas McMillin, Iris Breitkreutz, Yu-Tzu Tai, Boris Lin, Irene Ghobrial, Nikhil Munshi, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson
Journal: Blood (2006)
Fatal CNS trichinosis
Authors: T. Gay
Journal: JAMA (1982)

CENTRAL nervous system involvement by trichinosis has been recognized since the early part of this century.<sup>1</sup>The reported incidence of trichinosis in the United States now averages less than 150 cases a year.<sup>2</sup>Because only a small percentage of infected patients have CNS involvement, many physicians might fail to recognize this entity. We report the case of a patient who died of CNS trichinosis. <h3>Report of a Case</h3> A 50-year-old woman from southwestern Louisiana was in excellent health until late April 1980, when intermittent diarrhea and nausea developed. On May 13, she noted headache, photophobia, myalgias, and periorbital edema. She was admitted to a local hospital with a temperature of 39.5 °C and a WBC count of 12,800/cu mm, with 10% eosinophils. Dexamethasone therapy for a presumed allergic reaction resulted in improvement. When the dexamethasone administration was discontinued after ten days, fever and myalgias returned. Seizures and a
NIH Consensus Panel Issues Report—The Use of Diagnostic Ultrasound Imaging in Pregnancy
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article NIH Consensus Panel Issues Report—The Use of Diagnostic Ultrasound Imaging in Pregnancy Get access JNCI: Journal of the National Cancer Institute, Volume 73, Issue 4, October 1984, Page 1004, https://doi.org/10.1093/jnci/73.4.1004-a Published: 01 October 1984
Social Medicine and Medical Economics
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Something Sweet
Authors: Michael A. LaCombe
Journal: JAMA (1987)

I wish to relate to you the strange tale of J. Barrington Steep. You know the man. His office fronts on J—Street just down from Brolio's Restaurant. You must have looked in when upon a stroll at night. The red damask walls, the row upon row of legal tomes, the vast teak desk, the stuffed heads of impala, gazelle, nilgai—all lit indirectly and just so, all advertisements of a sort, all bespeaking the man. Last week I was something of a guest at a party of his, a monologue more likely, or a diatribe. He fairly railed at us. "My life is in shambles, I tell you, falling apart... and I have no control.<i>I</i>should be doing the summoning. Instead, I am called at 3:30 in the morning for nothing, repeatedly called, my household alarmed, and then... for nothing. Halfdressed, tearing from the house for some minor squabble, for
STEM CELLS
Authors: K. Joshi, S. Gupta, S. Mazumder, Y. Okemoto, B. Angenieux, H. Kornblum, I. Nakano, M. Synowitz, J. Kumar, S. Petrosino, R. Imperatore, E. Smith, P. Wendt, B. Erdmann, U. Nuber, U. Nuber, V. Matiash, S. Chirasani, L. Cristino, V. DiMarzo, H. Kettenmann, R. Glass, L. Soroceanu, L. Matlaf, C. Cobbs, Y.-W. Kim, S. H. Kim, C. Kwon, D.-y. Han, E. H. Kim, J. H. Chang, J.-L. Liu, Y. H. Kim, S. Kim, P. M. Long, M. S. Viapiano, D. M. Jaworski, Y. Kanemura, T. Shofuda, D. Kanematsu, Y. Matsumoto, A. Yamamoto, M. Nonaka, S. Moriuchi, S. Nakajima, H. Suemizu, M. Nakamura, Y. Okada, H. Okano, M. Yamasaki, R. L. Price, J. Song, K. Bingmer, P. Zimmerman, A. Rivera, J.-Y. Yi, C. Cook, E. A. Chiocca, C.-H. Kwon, S.-G. Kang, H.-D. Shin, H.-S. Mok, N.-R. Park, J. K. Sim, H. J. Shin, Y. K. Park, S. S. Jeun, Y.-K. Hong, F. F. Lang, B. A. McKenzie, F. J. Zemp, X. Lun, A. Narendran, G. McFadden, E. Kurz, P. Forsyth, C. E. Talsma, C. G. Flack, T. Zhu, X. He, M. Soules, J. A. Heth, K. Muraszko, X. Fan, L. Chen, H. Guerrero-Cazares, L. Noiman, C. Smith, N. Beltran, A. Levchenko, A. Quinones-Hinojosa, P. Peruzzi, J. Godlewski, S. E. Lawler, E. A. Chiocca, S. Sarkar, A. Doring, X. Lun, X. Wang, J. Kelly, W. Hader, J. F. Dunn, D. Kinniburgh, S. Robbins, P. Forsyth, G. Cairncross, S. Weiss, V. W. Yong, A. Vollmann-Zwerenz, N. Velez-Char, B. Jachnik, P. Ramm, P. Leukel, U. Bogdahn, P. Hau, S.-H. Kim, M. K. Lee, Y.-J. Chwae, B. C. Yoo, K.-H. Kim, K. Kristoffersen, M.- T. Stockhausen, H. S. Poulsen, M. Kaluzova, R. Machaidze, M. Wankhede, C. G. Hadjipanayis, A. M. Romane, F. J. Sim, S. Wang, D. Chandler-Militello, X. Li, Y. Al Fanek, K. Walter, M. Johnson, P. Achanta, A. Quinones-Hinojosa, S. A. Goldman, N. Shinojima, A. Hossain, T. Takezaki, J. Gumin, F. Gao, F. Nwajei, V. Cheung, J. Figueroa, F. F. Lang, S. Pellegatta, F. Orzan, E. Anghileri, S. Guzzetti, P. Porrati, M. Eoli, G. Finocchiaro, J. Fu, D. Koul, S. Wang, J. Yao, J. G. Gumin, E. Sulman, F. Lang, K. K. Aldape, H. Colman, A. W. Yung, D. Koul, J. Fu, J. Yao, S. Wang, J. Gumin, E. Sulman, F. Lang, K. Aldape, H. Colman, A. W. Yung, M. M. Alonso, L. Manterola, L. urquiza, N. Cortes-Santiago, R. Diez-Valle, S. Tejada-Solis, J. Garcia-foncillas, J. Fueyo, C. Gomez-Manzano, S. Nguyen, O. Stechishin, A. Luchman, S. Weiss, J. D. Lathia, J. Gallagher, M. Li, J. Myers, A. Hjelmeland, A. Huang, J. Rich, K. Bhat, B. Vaillant, V. Balasubramaniyan, R. Ezhilarasan, E. Sulman, H. Colman, K. Aldape, J. D. Lathia, M. Hitomi, J. Gallagher, S. Gadani, M. Li, J. Adkins, A. Vasanji, Q. Wu, A. Soeda, R. McLendon, A. Chenn, A. Hjelmeland, D. Park, J. Rich, J. Yao, J. Fu, D. Koul, J. N. Weinstein, W. K. Alfred Yung, D. Zagzag, M. Esencay, D. Klopsis, M. Liu, A. Narayana, E. Parker, J. Golfinos, P. A. Clark, I. K. Kandela, J. P. Weichert, J. S. Kuo, S. D. Fouse, R. P. Nagarajan, J. Nakamura, C. D. James, S. Chang, J. F. Costello, X. Gong, G. Kankar, K. Di, A. Reeves, M. Linskey, D. A. Bota, R. S. Schmid, R. E. Bash, M. Vitucci, A. M. Werneke, C. R. Miller, E. Kim, M. Kim, K. Kim, J. Lee, F. Du, P. Li, R. Wechsler-Reya, Z.-j. Yang
Journal: Neuro-Oncology (2011)
Time-oriented patient records and a computer databank
Authors: J. F. Fries
Journal: JAMA (1972)

Changes in clinical variables with time are critically important for evaluation of patient course, prognosis, and response to therapy. Traditional medical recording relates the individual observation to a "normal" value rather than to previous and subsequent observations. In a "time-oriented patient record," the record displays changes in clinical data with time, utilizing a "flow sheet" format. This record facilitates chart review and encourages use of data rather than memory in management decisions. The record is computer-compatible and permits development of a computer databank which may be flexibly utilized to answer a large variety of clinical questions. Patient status may be summarized, variables cross-correlated, clinical conditions reviewed, prognostic indicators measured, and response to various therapies compared. This type of computer record facilitates direct analysis of primary data and is a possible adjunct to traditional review of the literature. Output may be used for formal scientific study, for informal discussion, or for assistance in management of the individual patient.